BiotechTube

Zimura + Eylea

Phase 2Withdrawn
2 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Polypoidal Choroidal Vasculopathy

Conditions

Idiopathic Polypoidal Choroidal Vasculopathy

Trial Timeline

Nov 1, 2018 → Dec 1, 2019

NCT ID
NCT03374670

About Zimura + Eylea

Zimura + Eylea is a phase 2 stage product being developed by Astellas Pharma for Idiopathic Polypoidal Choroidal Vasculopathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03374670. Target conditions include Idiopathic Polypoidal Choroidal Vasculopathy.

What happened to similar drugs?

20 of 20 similar drugs in Idiopathic Polypoidal Choroidal Vasculopathy were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
✅Omalizumab + PlacebosNovartisApproved
✅Nintedanib + PirfenidoneRocheApproved
✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved
✅TocilizumabRocheApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03374670Phase 2Withdrawn

Competing Products

20 competing products in Idiopathic Polypoidal Choroidal Vasculopathy

See all competitors
ProductCompanyStageHype Score
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
Avacincaptad PegolAstellas PharmaPhase 2
35
Rituximab + cyclosporineSun PharmaceuticalPhase 3
32
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
PerampanelEisaiPre-clinical
26
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
40